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Abstract
Parkinson’s disease (PD) is the second most common neurodegenerative disorder of aging. The pathological hallmark of PD
is neuronal inclusions termed Lewy bodies whose main component is alpha-synuclein protein. The finding of these Lewy
bodies in the intestinal enteric nerves led to the hypothesis that the intestine might be an early site of PD disease in
response to an environmental toxin or pathogen. One potential mechanism for environmental toxin(s) and proinflammatory
luminal products to gain access to mucosal neuronal tissue and promote oxidative stress is compromised intestinal barrier
integrity. However, the role of intestinal permeability in PD has never been tested. We hypothesized that PD subjects might
exhibit increased intestinal permeability to proinflammatory bacterial products in the intestine. To test our hypothesis we
evaluated intestinal permeability in subjects newly diagnosed with PD and compared their values to healthy subjects. In
addition, we obtained intestinal biopsies from both groups and used immunohistochemistry to assess bacterial
translocation, nitrotyrosine (oxidative stress), and alpha-synuclein. We also evaluated serum markers of endotoxin exposure
including LPS binding protein (LBP). Our data show that our PD subjects exhibit significantly greater intestinal permeability
(gut leakiness) than controls. In addition, this intestinal hyperpermeability significantly correlated with increased intestinal
mucosa staining for E. coli bacteria, nitrotyrosine, and alpha-synuclein as well as serum LBP levels in PD subjects. These data
represent not only the first demonstration of abnormal intestinal permeability in PD subjects but also the first correlation of
increased intestinal permeability in PD with intestinal alpha–synuclein (the hallmark of PD), as well as staining for gram
negative bacteria and tissue oxidative stress. Our study may thus shed new light on PD pathogenesis as well as provide a
new method for earlier diagnosis of PD and suggests potential therapeutic targets in PD subjects.
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Introduction
Parkinson’s disease (PD) is the second most common neurode-
generative disorder of aging, and is projected to affect nearly 10
million citizens of the world’s most populous countries by 2030
[1,2]. The burden of disability from PD is considerable [3].
Unfortunately there is no optimal treatment for PD and this is at
least partly because the majority of patients with PD will be
diagnosed and receive treatment after the onset of neurological
symptoms when substantial neuronal dysfunction and neuronal
loss has already occurred. Thus, a more successful approach could
be to diagnose and start treatment before neuronal degeneration
results in the emergence of clinical signs of PD. In fact, although
the etiology of PD is not known, the pathobiology of neuronal loss
in PD is well characterized. It is now well established that the
pathological hallmark of PD are neuronal inclusions termed Lewy
bodies (LB) or Lewy neurites (LN) whose main component is
aggregated and phosphorylated a-synuclein [4,5]. It is believed
that these a-synuclein aggregates are the first steps resulting in
neuronal loss that is responsible for neurological symptoms and
signs of PD [5]. A better understanding of how a-synuclein
aggregates form will be a key for advancing our understanding of
the pathogenesis of PD that could lead to early diagnosis and
treatment with potentially much better outcome.
While phosphorylated a-synuclein aggregates may be formed as
a consequence of oxidative injury [4], the source of neuronal
oxidative stress in PD is not known. It is believed that PD
pathology is a consequence of interaction between genetic
susceptibility and toxic environmental factors [6]. It is highly
plausible that the gastrointestinal (GI) tract is a major site and
source of oxidative stress in neuronal tissue based on the following:
(1) The GI tract is the largest interface between neural tissue and
the environment. (2) The GI tract has a large number of neuronal
cells in the submucosal plexus and myentric plexus, large enough
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More importantly, this neuronal network is in close proximity to
the potentially injurious factors such as bacterial products capable
of inducing oxidative stress [8]. (3) The GI lumen harbors the
largest and most diversified human associated microbiota
community with the capability of inducing inflammatory and
oxidative pathways [9]. The composition of this bacterial
community is influenced by both genetic and environmental
factors like diet [10]. (4) The GI system and the brain are directly
linked anatomically with the dorsal motor nucleus of the vagus
nerve, a brain region proposed to express Lewy pathology very
early in the disease process [5]; and (5) critically, one important
function of the GI tract is to act as a semipermeable barrier, which
allows regulation of nutrient, ion and water absorption, and
regulates host contact with a large number of dietary antigens and
bacterial products [11]. Intestinal permeability can be defined as
the facility with which the intestinal epithelium allows molecules to
pass through by non-mediated passive diffusion. Several chronic
autoimmune intestinal diseases including inflammatory bowel
disease and celiac disease are associated with increased intestinal
permeability also known as ‘‘leaky gut’’ [12,13]. Thus, gut
leakiness in patients with a genetic susceptibility to PD may be a
pivotal early step promoting a pro-inflammatory/oxidative
environment contributing to the initiation and/or progression of
the PD process. One particularly detrimental consequence of
increased intestinal permeability is the translocation of bacteria
(e.g., E. Coli) and bacterial products (e.g., lipopolysaccharide (LPS)
also known as endotoxin) which creates a proinflammatory
environment and increases the oxidative stress burden in the
enteric nervous system. Indeed, it has been suggested that the GI
tract might be a portal of entry for a putative PD pathogen,
triggering pathological changes in the submucosal/myenteric
neurons, which then spread through the vagus nerve to the
medulla oblongata [14,15]. From there, pathological changes may
move rostrally, ultimately resulting in the clinically-defining motor
symptoms of PD when there is extensive involvement in the
middle portion of the disease at the level of the midbrain
substantia nigra [5]. Thus, the involvement of the GI tract in PD is
of great interest as a contributing factor to the development and
progression of PD.
To date, intestinal permeability has not been investigated in
patients with PD. Accordingly, we hypothesized that PD subjects
might have increased intestinal permeability leading to increased
exposure of intestinal neuronal tissue to bacterial derived pro-
inflammatory products resulting in oxidative stress and neuronal
pathological a-synuclein aggregates. To this end, the objectives of
this study were to: i) assess intestinal permeability in subjects with
newly diagnosed, untreated PD and compare the results to
controls without a history of neurological disease or PD; ii)
determine whether increased intestinal permeability (‘‘leaky gut’’)
in PD subjects correlated with markers of bacterial translocation
and endotoxin exposure either locally or systemically, and iii)
determine whether gut leakiness is associated with mucosal
oxidative stress and intestinal neuronal a-synuclein aggregates.
Results
We studied 9 subjects (6 men) with PD (see flow diagram Fig. 1).
Subject demographics and disease duration and bowel movement
(BM) characteristics are shown in Table 1. Median age was 57.
Median duration of PD from first symptom onset was 2 years.
Median total Unified Parkinson’s Disease Rating Scale (UPDRS)
score was 24; median Hoehn & Yahr stage was 2. No patient took
levodopa or dopamine agonists, although one took amantadine.
Figure 1. Consort 2010 flow diagram of this study. 12 research subjects were invited to participate in this study. Two were excluded because
they failed to meet inclusion criteria (prohibited medications). One study subject incorrectly performed the 24-hour urine collection for intestinal
permeability testing and his data were excluded from analysis. Nine study subjects completed all study assessments.
doi:10.1371/journal.pone.0028032.g001
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constipation. PD subjects were compared to ten age-matched
control subjects (7 men), median age 49 with no signs or symptoms
of neurological diseases or other chronic diseases (no PD vs.
Controls statistical age difference by Mann-Whitney). No bleeding,
fever, pain or other side effects of any procedures were detected in
any subjects.
Parkinson’s disease subjects have significantly increased
whole gut permeability to sucralose
Twelve hour urinary lactulose or mannitol as well as the L/M
ratio in subjects with PD were similar to the values obtained for
controls (Fig. 2). In contrast, 24 hour urinary sucralose (marker of
total intestinal permeability) was significantly increased in PD
subjects (Fig. 3). As seen in Figure 3, the mean 24 h urinary
sucralose (expressed as percent of oral dose) was significantly
greater (about double versus controls) in PD subjects (1.1260.1)
compared to age matched controls (0.586.1) (p,0.05).
PD subjects show significant evidence of increased
exposure to intestinal bacteria and bacterial endotoxin
To determine if the increased intestinal permeability observed
in PD subjects was associated with increased translocation of
intestinal bacterial products, we stained sigmoid mucosa slides
with polyclonal Ab for the gram negative bacteria E. Coli.W e
found that there was significantly more intense staining of E. coli in
both epithelial and lamina propria zones of sigmoid mucosa
samples from patients with PD compared to controls (Table 2).
Furthermore, there was a significant correlation (Pearson’s
r=0.632; p,0.05) between intensity score for lamina propria
zone staining of E. coli and urinary sucralose (intestinal
permeability) in PD patients (Table 3). Thus, these results not
Table 1. Parkinson’s Disease Subject Characteristics.
Age (Y)/Sex Disease Duration (Y) UPDRS Score HY Stage BM/week Diarrhea Constipation
75M 4 28 2 4 n n
68F 0.5 24 2 14 n n
66M 1 27 2 7 n n
61M 1 18 2 7 n n
57M 2 28 2 10 n n
56F 1 15 1.5 10 n n
55M 4 28 2 7 n n
47M 8 18 2 10 n n
46F 2 16 1 5 n n
Median 57 2 24 2 7 - -
doi:10.1371/journal.pone.0028032.t001
Figure 2. Intestinal permeability to lactulose and mannitol is similar in control and PD subjects. PD subjects and healthy controls were
assessed for intestinal permeability using an oral sugar solution containing sucrose, lactulose, mannitol, and sucralose and GC analysis of 24 hour
urine samples as described in Materials and Methods. Urinary lactulose and mannitol as well as the L/M ratio (all primarily measures of small intestinal
permeability) were not significantly different in PD patients compared to controls. Data are presented as mean % urinary excretion of the oral dose in
24 hours 6 SE. * p,0.05.
doi:10.1371/journal.pone.0028032.g002
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subjects have increased colonic permeability), it also suggests that
enhanced permeability in PD subjects may have potentially
significant biological consequences resulting from increased
exposure of neuronal tissues in mucosa and possibly sub-mucosal
(lamina propria) parts of the colonic wall to bacterial products
including endotoxin. As another index of intestinal permeability,
systemic exposure to intestinal bacterial products was determined
by measuring plasma LPS binding protein (LBP) [16,17]. Lower
levels of plasma LBP have been associated with increased exposure
to gram negative bacteria [16,18]. As shown in Fig. 4, PD subjects
had a significantly lower mean level of plasma LBP compared to
normal subjects (PD 2285665540 ng/ml vs. Control
84291631380 ng/ml). Other measures of systemic endotoxin
exposure such as serum endotoxin, plasma IgG endocab (native
Ab to LPS), and serum soluble CD14 were not different between
the PD and control groups (Table 4). Taken together these plasma
LBP and E. coli staining data support increased intestinal
permeability to gram negative bacteria and bacterial products in
PD subjects.
Increased intestinal biopsy staining for a-synuclein and
3-nitrotyrosine (3-NT) correlate significantly with intestinal
hyperpermeability and E. coli staining in PD subjects
We next wished to examine if increased intestinal permeability
to inflammatory bacterial products measured in PD subjects was
correlated with intestinal markers of PD (e.g., a-synuclein) and
inflammation/oxidative stress (e.g., nitrotyrosine). We have
recently demonstrated that these PD subjects exhibit significantly
increased intestinal staining for both a-synuclein and nitrotyrosine
[19]. To further investigate the relationship between permeability
to bacterial products, a-synuclein, and nitrotyrosine staining we
re-stained intestinal biopsies from PD subjects and controls using
antibodies to all three markers. Fig. 5 shows representative images
from both a PD subject (A–F) as well as a control subject (G–I)
using the same field of view from each respective tissue sample.
Clearly, the tissue from the PD subject shows significantly greater
staining for E. coli, a-synuclein and nitrotyrosine when compared
to the control subject tissue staining. To determine whether
increased gut leakiness and increased exposure to LPS are
associated with oxidative stress (nitrotyrosine staining) and PD
neuronal injury (a-synuclein staining) in these subjects, we
determined Spearman’s ‘‘r’’ correlation coefficients between
urinary sucralose levels with the intensity staining scores of E.
coli staining, a-synuclein staining and nitrotyrosine staining for all
PD subjects and controls (Table 3). Very importantly, we found
that increased intestinal permeability (i.e., urinary sucralose) and
E. coli staining significantly correlated with a-synuclein staining in
PD subjects but not in controls. Remarkably, increased urinary
sucralose, E. coli staining, and a-synuclein staining also each
significantly correlated with increased intestinal staining for
nitrotyrosine in PD subjects but not in healthy controls.
Discussion
GI symptoms such as constipation and bloating are the most
common non-motor symptoms in PD patients [20]. It is generally
believed that these symptoms are a consequence of PD and are the
result of intestinal motility disorders and the associated intestinal
bacterial overgrowth. However, over the last decade there has
been mounting evidence that supports a role for the GI tract and
the enteric nervous system (ENS) in the pathogenesis of PD [7,15].
Two early studies found the first GI Lewy bodies (LBs) in the
Figure 3. Intestinal permeability to sucralose is significantly greater in PD patients. PD subjects and healthy controls were assessed for
intestinal permeability using an oral sugar solution containing sucrose, lactulose, mannitol, and sucralose and GC analysis of 24 hour urine samplesa s
described in Materials and Methods. Urinary sucralose, a measure of whole intestine permeability, was significantly greater in PD subjects vs. healthy
age matched controls. Data are presented as mean % urinary excretion of the oral dose in 24 hours 6 SE. * p,0.05.
doi:10.1371/journal.pone.0028032.g003
Table 2. E. coli Staining Scores for Intestinal Tissue.
Group Score for Intensity of E. coli Staining
Lumen Lamina Propria Epithelial Crypt
Control 2.5 (0–3) 0.5 (0–4) 1 (0–3) 0 (0–3)
Parkinson 3 (1–3) 2* (1–4) 2.5* (2–4) 3 (0–3)
*Correlation is significant at the 0.05 level (2-tailed).
Scores are shown as medians and (ranges).
doi:10.1371/journal.pone.0028032.t002
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third group substantiated these early findings of LB pathology in
both the submucosal plexis (SMP) and myenteric plexis (MP) in the
ENS of PD patients [23,24,25]. Recently, Lewy bodies were found
in colonic biopsies from 4 out of 5 [26] and 21 out of 29 [27] PD
patients, but in none of the controls. It is notable that all of these
prior studies used later stage patients. The similarity of our
findings in early untreated patients suggests that this pathology is
unrelated to drug treatment and supports the concept for GI-
related parameters to serve as a biomarker for the disease.
None of our subjects complained of constipation and the
frequency of bowel movement in all subjects were within normal
range. These data are now included in Table 1. In fact, we
designed the study as such to minimize the potential confounding
effects of constipation due to longstanding Parkinson’s disease and
included only newly diagnosed PD patients. Thus, it is unlikely
that constipation played a role in any of our findings. Although we
did not directly study small bowel bacterial overgrowth, none of
the patients complained of bloating and there is no known
physiological reason for small bowel bacterial overgrowth to cause
disruption of colonic permeability. Of course changes in colonic
microbiota could play a critical role in changes in colonic
permeability in PD patients because there is compelling evidence
of cross talk occurring between the colonic microbiota and
intestinal epithelial cells. Indeed, part of our broad hypothesis is
that changes in colonic microbiota could play a mechanistic role in
our observed intestinal hyperpermeability and further studies are
needed to interrogate intestinal microbiota in patients with PD.
While compelling, these observations do not necessarily suggest
a causal role for the intestines in the pathogenesis of PD and could
simply indicate widespread neuronal damage resulting from PD.
However, these findings by others, as well as by Braak and
colleagues, led to the proposal [14,15] that the ENS may be a
route by which a toxin or pathogen initiates the progression of PD
over a period of many years. In support, a pathway of a-synuclein
expressing neurons from the gut to the CNS was recently shown
[28]. A recent publication from our group has shown a-synuclein
staining positive sigmoid mucosal neuronal tissue in all 9 of the
early untreated PD patients examined in this present study[29],
while none of the control samples exhibited substantial staining
indicating these processes occur early on in the pathogenesis of
PD. None the less, these observations still do not prove that PD
pathology begins in the ENS and they may simply represent
progression of PD pathology that could explain the high frequency
of GI symptoms in PD patients [7]. Further longitudinal studies
are needed to determine whether a-synuclein staining in the
intestinal mucosa is present in PD patients years prior to onset of
clinical neurological evidence of PD.
Figure 4. Plasma LBP is significantly lower in PD patients. Plasma levels of LPS binding protein (LBP), an indirect measure of systemic
endotoxin exposure, were determined for PD subjects and healthy controls as described in Materials and Methods. Values for plasma LBP in PD
subjects were significantly lower than in healthy controls. Data are presented as means (ng/ml) 6 SE. *p,0.05.
doi:10.1371/journal.pone.0028032.g004
Table 3. Spearman’s r Correlation Values.
Score for Intensity of E. coli Staining
Nitrotyrosine Sucralose
Plasma
LBP Lumen
Lamina
propria Epithelial Crypt
a-Synuclein 0.911** 0.588* 20.853** 20.181 0.632* 0.330 0.133
Nitrotyrosine NA 0.609* 20.822* 20.284 0.539* 0.312 0.266
Sucralose 0.609* NA 20.475 20.128 0.672* 0.121 0.174
**Correlation is significant at the 0.01 level (2-tailed).
*Correlation is significant at the 0.05 level (2-tailed).
doi:10.1371/journal.pone.0028032.t003
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primary or secondary events in PD, in order to better understand
its role in PD, we need to determine the mechanism of their
development. It is now widely believed that a-synuclein
aggregates are the consequence of oxidative injury to neurons
[4]. It is also well established that inflammation and pro-
inflammatory cytokines like IL-1b, IL-6 and TNF-a are one
major source of tissue oxidative stress [30]. Indeed, neuroin-
flammation is present within the brain of early PD patients [31]
and considerable evidence supports a role for neuroinflammation
in PD pathogenesis [30,32].
Thus, it is a reasonable and plausible hypothesis that ENS a-
synuclein aggregates are the consequence of a local pro-
inflammatory milieu. Braak and colleagues propose that toxin
and/or pathogen presence in the intestinal lumen may trigger
neuroinflammation. However, it should be noted that the presence
of toxins and/or pathogens might not necessarily supply the
required trigger because even healthy subjects have a large
amount of luminal proinflammatory products resulting from
normal intestinal microbiota including endotoxins. It is more
Table 4. Measures of Endotoxin Exposure.
Endotoxin
(EU/ml)
sCD14
(ng/ml)
Endocab IgG
(GMU/ml)
LBP
(ng/ml)
Controls
(mean 6 SE)
0.8216208 20226143 488680 84291631380
Parkinson
(mean 6 SE)
0.8406.127 2007676 433654 2285665540
P value 0.71 0.88 0.68 *0.016
*PD vs. Control difference is significant at the 0.05 level (2-tailed).
doi:10.1371/journal.pone.0028032.t004
Figure 5. Immunohistochemical staining of intestinal biopsies for E. coli, a-synuclein, and 3-NT is significantly greater in PD
subjects. Intestinal biopsies from PD subjects and healthy controls were formalin fixed, paraffin embedded, and then cut to 5 mm and processed as
described in Materials and Methods for each respective antibody to either E.coli gram negative bacteria (A,D,G), a-synuclein (B,E,H) or 3-nitrotyrosine
(3-NT)(C,F,I). Representative images are shown from a PD subject at 156(A–C) and 406(D–F) magnification using the same field of view and from a
healthy control subject (G–I) at 406. Staining data were analyzed by blinded observers and PD subjects were found to stain significantly greater for E.
coli, a-synuclein, and 3-NT. Scale bars=A–C 50 mm, D–I 100 mm.
doi:10.1371/journal.pone.0028032.g005
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gut) and translocation of these substances is the critical factor for
intestinal neuronal oxidative injury. Several lines of evidence
strongly suggest that endotoxins are plausible neuroinflammatory
triggers in PD. First, endotoxin (LPS) has been suggested as one
environmental trigger of PD [33]. Second, LPS administration
either systemically or directly into the CNS is a widely used animal
model of PD. For example, mice given a single dose of LPS
systemically [34] or prenatally [35] develop CNS inflammation
including selective loss of DA neurons in the substantia nigra (SN)
[34]. In the present study we showed evidence of excessive
endotoxin exposure in PD patients because serum LPS binding
proteins were significantly lower in PD patients compared to
controls. Generally, lower levels of LBP have been shown to
support increased proinflammatory signaling and cytokine pro-
duction by endotoxin [16]. To the best of our knowledge, our
finding is the first to show increased bacterial/endotoxin exposures
in PD. It should be noted that we did not find significant increase
in serum endotoxin in PD patients. We believe that our findings of
significant changes in LBP and positive staining of E.coli antigen in
the colonic biopsies strongly suggest that our observed increased
intestinal permeability in PD has significant biological conse-
quence resulting in exposure of intestinal mucosa and the mucosal
immune system to the luminal bacteria products. However, the
translocation of luminal bacteria products could be limited to the
colonic submucosa leading to oxidative injury to the colonic
mucosa neurons and aggregation of a-synuclein. Another
possibility is that leaked endotoxin could reach the portal systemic
circulation but is cleared by the liver and thus a high level of
endotoxin was not observed in our patients. Regardless, even if
leaked endotoxin cannot reach the circulation, it still can play a
central role in production of a-synuclein aggregates in the colon
and pathogenesis of PD. Endotoxins (or gram negative bacteria
such as E. coli) can bind to and thus be trapped in the intestinal
mucosa and not reach the systemic circulation. Positive E. coli
staining in the sigmoid mucosa of our PD patients not only further
supports the conclusion of increased permeation of endotoxins
across intestinal epithelial cells, it also supports the possibility that
endotoxins become trapped in the intestinal mucosa. It should also
be noted that endotoxins might be directly involved in initiation
and/or progression of neuroinflammatory injury in both the ENS
and CNS in PD without systemic endotoxemia [36]. Further
studies are needed to evaluate whether there is cell loss in the
enteric nervous system associated with a-synuclein aggregates in
our PD subjects
How does endotoxin promote neuroinflammation? One
possibility is that endotoxins stimulate the enteric immune
response either directly or via glial cells to promote local oxidative
stress leading to a-synuclein misfolding, aggregation, and subse-
quent neuronal damage in the ENS in individuals genetically
susceptible for PD. Indeed, we have shown an increased
nitrotyrosine staining indicating increased oxidative stress in the
sigmoid mucosa of PD patients and this increase correlated with
plasma LBP and intensity of intestinal E. coli staining. Our finding
that serum sCD14 levels in PD patients was not significantly
increased suggests that macrophages are not involved in
endotoxin-induced neuroinflammation because activation of
macrophages by endotoxin through ligation with TLR4 results
in shedding of sCD14 and increased levels of sCD14 in the blood
[37]. However, it is possible that shedding of sCD14 in the
intestinal mucosa is not reflected in the serum measurement. It
should also be noted that endotoxins can trigger immune-
inflammatory pathways via TLR4 ligation without requirement
of CD14 in non-macrophage immune cells [38].
If indeed endotoxins cause neuroinflammation then why does
this occur only in individuals susceptible for PD? First, neuronal
tissues in those susceptible to PD may be more sensitive to the
endotoxin effects. There are several experimental findings to
support this possibility. Rodent nigral neurons have been shown to
be more vulnerable than either hippocampal or cortical neurons to
LPS-induced degeneration in vivo and in vitro, and this was shown
to be due to the higher number of activated microglia per unit area
in the SNpc compared with the other brain regions [39]. Inherent
processing of a-synuclein may also play a role. Transgenic mice
overexpressing human A53T mutant a-synuclein were given LPS
systemically (i.e., i.p. injection). Only the transgenic mice, and not
controls, developed sustained neuroinflammation including Lewy
bodies staining of nigral neurons [40]. This supports a synergistic
interaction between defective a-synuclein processing and endo-
toxin exposure in promoting PD-related nerve pathology.
Second, endotoxin-mediated neuronal damage might not be
limited to PD. For example, normal human rectal tissue biopsies
incubated with LPS exhibit increased enteric glial cell oxidative
stress burden (i.e., iNOS production) [41], a possible source for the
observed nitrotyrosine staining in our subjects. Furthermore, co-
culture of rat enteric neurons and enteroglial cells stimulated with
LPS results in increased glial cell production of proinflammatory
cytokine IL-1b [42]. It is therefore not surprising that endotoxemia
has been reported in other neurological disorders like autism, ALS,
and depression [43,44] [45].
Another question that needs to be answered is what is the cause
of increased endotoxin exposure in PD? One obvious mechanism
is increased intestinal permeation to endotoxin (i.e., gut leakiness).
We show here that PD patients have a ‘‘leaky gut’’. PD patients
not only had marked and significant increased urinary sucralose,
they also had increased intensity of E. coli staining in the deep zone
of the sigmoid mucosa. Thus, PD patients appear to have a
hyperpermeable intestinal epithelium and this may have the
important biological consequence of a significantly increased
exposure to endotoxins, oxidative stress, and neuronal injury to the
ENS. The increase in urinary sucralose with no significant change
in urinary lactulose or L/M ratio in PD patients strongly suggests
that the site of enhanced leakiness is the colon. To our knowledge,
intestinal permeability has previously been evaluated in PD
subjects in only one other study [46]. In that study they found
PD patients exhibited decreased absorption of mannitol resulting
in an increased L/M ratio. However sucralose absorption was not
tested as we have shown in our study and very significantly the
median age of those patients was 73.9 y/o (vs. 57 y/o in our study)
and all had responded to L-dopa therapy (vs. no therapy in our
study). Also, no intestinal biopsy staining for a-synuclein or
markers of endotoxin was carried out. Thus we are the first to
demonstrate increased intestinal permeability and its significant
association with increased intestinal exposure to endotoxin,
intestinal oxidative stress, and intestinal a-synuclein aggregation
in early, untreated PD patients.
In summary, our study presents data for a new model for PD
pathogenesis involving increased intestinal permeability to proin-
flammatory bacteria and bacterial products such as endotoxins
(i.e., LPS). This model provides for an easily obtained, inexpensive
biomarker that may be useful in identifying those individuals with
premotor PD that will get classic PD signs and symptoms later in
life. Our data demonstrate that increased intestinal permeability
strongly correlates with markers of increased exposure to
endotoxin and with a marker indicating increased oxidative stress
burden in the intestine, which together may be responsible for the
abnormal accumulation of a-synuclein in enteric neurons we also
observe as have other studies. Such increased bacterial endotoxin
Leaky Gut, Endotoxin, and Synuclein in Parkinson’s
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promoting PD in genetically susceptible individuals. We acknowl-
edge that our cross sectional observational study cannot establish a
causal relationship between increased permeability and PD
pathophysiology and that further interventional and animal studies
are needed to determine whether gut leakiness and a-synuclein
deposition in the colon have a causal role in the pathogenesis of
PD. These studies will be needed to determine whether increased
intestinal permeability plays a causative role in PD initiation or is a
consequence of PD pathogenesis. At the least, such a mechanism
for increased exposure of the ENS to intestinal endotoxin may fuel
the progression of PD in susceptible subjects.
Materials and Methods
Study Subjects and Ethics Statement
The protocol for this trial and supporting CONSORT checklist
are available as supporting information; see Checklist S1 and
Protocol S1. The study was reviewed and approved by the
Institutional Review Board at Rush University Medical Center,
and registered with Clinicaltrials.gov (NCT NCT01155492,
‘‘Increased Gut Permeability to Lipopolysaccharides (LPS) in
Parkinson’s Disease’’). No deviations from the approved trial
protocol were made in this study. All subjects provided written
informed consent. We recruited subjects with clinically diagnosed
Parkinson’s disease not yet requiring dopaminergic therapy. None
of our PD subjects exhibited symptoms of constipation. Consti-
pation was defined as fewer than 3 BM/week or if the subject
complained of constipation. Men and women who met United
Kingdom Parkinson Disease Research Society brain bank criteria
for PD, Hoehn & Yahr stage 1–2.5 [47] were included. Subjects
were excluded based on the following: atypical or secondary
Parkinsonism, any known organic gastrointestinal disease, use of
drugs affecting gastrointestinal motility, anti-inflammatory agents,
and chronic diuretic use. Control subjects were of similar age and
gender who had no GI or neurological symptoms or signs
(determined by examination by a board certified neurologist with
expertise in movement disorders) and were not taking regular
medication or anti-inflammatory agents.
Intestinal permeability measurement (primary outcome)
One way to assess intestinal permeability is by administration of
oral sugars (i.e., mannitol, lactulose, sucrose, and sucralose) and
analysis of subsequent sugar excretion in urine. Since these sugars
are not significantly metabolized in the body after absorption from
the intestine, excretion into the urine reflects intestinal permeabil-
ity [48]. Passageways (‘‘pores’’) formed by tight junctions between
GI epithelial cells range in size from 4–60 A ˚ and differentially
allow the passage of molecules. These characteristics in conjunc-
tion with attributes of each sugar allow for determination of
regional differences in GI permeability. Small molecules such as
mannitol traverse pores of all sizes, while larger molecules, such as
lactulose, can only pass through larger pores [11,48]. Sucrose is
rapidly degraded after leaving the stomach, so increased sucrose
excretion reflects gastric permeability and sucralose is absorbed
through large pores in the small and large intestine. Increased
urinary sucrose, lactulose/mannitol ratio and sucralose reflect
gastroduodenal, small intestinal and total gut (small bowel and
large bowel) hyperpermeability, respectively [48,49]. Increased
sucralose excretion in conjunction with normal lactulose/mannitol
ratio might reflect increased large intestinal (colonic) permeability
[48]. The rationale for using urinary sucralose as a reliable marker
of total gut permeability is that not only is sucralose relatively
uniformly absorbed in both small and large intestine it is also
available in the lumen of the colon for absorption because, unlike
lactulose and mannitol, it cannot be metabolized and consumed by
colonic bacteria.
Subjects fasted overnight and subsequently ingested a sugar
mixture containing 2 grams mannitol, 7.5 grams lactulose, 40 gm
sucrose, and 1 gram sucralose at 6AM, then collected 2 sequential
12-hour urine samples. Urine was analyzed for sugar content using
gas chromatography (GC) techniques. Measurement of urinary
sugars using GC is used to calculate intestinal permeability and is
expressed as percent oral dose excreted in the urine. We have
recently revised our method which briefly involves conversion of
the relevant sugars to their alditol acetate form rather than our
previous method of N-Trimethylsilylimidazole (TMSI) derivatiza-
tion and find it is a more sensitive method to detect the sugars.
This is thus a modification of our methods that we have previously
published [49,50].
Plasma and serum measures of endotoxin exposure
(secondary outcome)
Endotoxin was measured in serum by Limulus Amebocyte
Lysate QCL-1000 from Lonza (catalogue # 50-647U)(EU/ml).
Serum or plasma samples were diluted at 1:5 ratio with LAL
reagent water. Endotoxin IgG core antibodies were measured in
plasma using an ELISA kit from Cell Sciences Inc (catalogue #
HK504). Units are expressed as GMU/ml which are IgG standard
median units based on medians of ranges of 1000 healthy adults by
the manufacturer. Soluble CD14 (sCD14) (ng/ml) was measured
in serum by R&D systems quantikine immunoassay (catalogue #
DC140). Lipopolysaccharide binding protein (LBP)(ng/ml) was
measured in plasma using an ELISA kit from Cell Sciences Inc
(catalogue # HK315).
Immunohistochemistry staining for E. coli in intestinal
biopsies
Limited unprepped flexible sigmoidoscopy to the distal sigmoid
at around 20 cm from the anal verge was performed in control
and PD subjects by one of the authors (AK). No sedation was
required for the procedure, the duration of which was less than
10 minutes. No bleeding, fever, or other side effects were observed
or reported in any subject. Six cold biopsies were obtained from
normal appearing sigmoid colon using biopsy forceps. Samples
were snap frozen in liquid nitrogen at the time of collection. Biopsy
specimens used for staining were fixed in formalin and embedded
in paraffin. 5 mm thick sections were cut for E. coli, a-synuclein,
and 3-nitrotyrosine (3-NT) staining analysis. Immunohistochem-
istry for rabbit polyclonal anti-Escherichia coli (Cat. # B0357; Dako)
was performed using a biotin-free polymer approach (Rabbit
Prolink-1, Golden Bridge International, Inc.) on 5-mm tissue
sections mounted on glass slides, which were dewaxed and
rehydrated with double-distilled H2O. Antigen retrieval was
performed by heating sections in 16 DIVA Decloaker reagent
(Biocare Medical) in a pressure cooker set at 121uC for 30 sec.
Slides were stained with optimal conditions determined empiri-
cally on an IntelliPATH autostainer (Biocare Medical) that
consisted of a blocking step using blocking buffer (TBS with
0.05% Tween-20 and 0.5% casein) for 10 min and an endogenous
peroxidase block using 1.5% (v/v) H2O2 in TBS (pH 7.4) for
10 min. Primary Abs were diluted in blocking buffer and
incubated for 1 h at room temperature or overnight at 4uC.
Tissue sections were washed, and the Rabbit Prolink-1 staining
system (Golden Bridge International, Inc) was applied for 30 min
at room temperature. Sections were developed with Impact
TM
3,39-diaminobenzidine (Vector Laboratories), counterstained with
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stained slides were scanned at high magnification (2006) using the
ScanScope CS System (Aperio Technologies, Inc.) yielding high-
resolution data for the entire tissue section. Representative high
magnification (2006) images were acquired from these whole
tissue scans for scoring.
Using E. Coli IHC as a measure of intestinal permeability is an
approach which has recently been used successfully to assess
intestinal leakiness to bacterial contents in HIV patients [51].
Staining was quantitated by blinded scoring on a scale of 0–4 with
4 as the highest in four separate intestinal tissue zones: Lumen
(positive control), epithelium, lamina propria (LP), and crypts.
Immunohistochemistry staining for a-synuclein and
nitrotyrosine in intestinal biopsies
Sections were processed using an antigen-retrieval procedure.
Briefly, the sections were treated with 88% formic acid for 20 min
followed by citric acid (pH=6.0, at boiling temp) treatment for
20 min, then kept outside at 25uC and processed through three
washes of distilled water and three washes of phosphate buffer
solution (PBS). Sections were incubated in 3% normal horse serum
and 2% bovine serum albumin for an hour, then incubated in the
primary anti-a-synuclein (mouse anti-alpha synuclein, 1:500,
Invitrogen) or 3-NT (Millipore Inc; 1:500) antibody for 48 hrs at
4uC. The sections were washed, then sequentially incubated in the
secondary antibody (biotinylated horse anti-mouse, 1:200, Vector
Laboratories), phosphate buffer saline washes, and the ABC
solution (ABC kit, Vectastatin Elite, cat # PK-6100). The stain
was completed in a chromogen solution containing 0.05% 393
diaminobenzidine and 0.005% hydrogen peroxide. After stain
development, the sections were dried overnight, then coverslipped
with cytoseal (23244257, Fisher). The same procedure was
followed for brain slices including the substantia nigra which was
used as a positive control (not shown). Negative control sections
substituted an irrelevant IgG for primary antibody.
All immunostained slides were reviewed and rated for presence
and intensity of a-synuclein and 3-NT staining by a blinded rater
(HD) according to a 5 point scale with 0=no immunostaining and
4=very intense immunostaining.
Statistical analysis
Unless otherwise noted, Data are presented as means 6 SE. For
non parametric analyses of two groups, we used Mann-Whitney
U; (Figs. 2, 3, and 4 and Table 4).Correlational analyses were done
using the Spearman test for nonparametric analysis (Table 3). For
E. coli staining scores are shown as medians with the range
(Table 2). P values,.05 were deemed statistically significant. All
analysis except power analysis was performed using the SPSS
statistical software (IBM, Armonk, NY). For power analysis
intestinal permeability sucralose measurements were used. The
means for sucralose percent urinary excretion of oral dose 6 SE
were 0.5860.1, 1.1260.1 in control and treatment groups
respectively. For N=10 in control and N=9 in the PD group,
with the alpha level at 0.05, a one sided test was applied and the
power for our study is 0.80708 (81%). All power calculations were
done in PASS (PASS 2008. NCSS, LLC. Kaysville, Utah).
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